Concord Biotech
Concord Biotech Ltd, a leading biopharmaceutical company headquartered in India, has established itself as a key player in the global biotechnology industry since its inception in 2000. With a strong focus on the development and manufacturing of biopharmaceuticals, the company operates primarily in India and has expanded its reach to various international markets. Specialising in the production of biosimilars and active pharmaceutical ingredients (APIs), Concord Biotech is renowned for its commitment to quality and innovation. The company’s core products include a range of biosimilars that cater to therapeutic areas such as oncology and autoimmune diseases, setting them apart through rigorous research and development processes. Recognised for its significant contributions to the biopharmaceutical sector, Concord Biotech has achieved notable milestones, including successful product launches and strategic partnerships, solidifying its position as a trusted name in the industry.
DitchCarbon Score
How does Concord Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Concord Biotech's score of 27 is higher than 52% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Concord Biotech's reported carbon emissions
In 2024, Concord Biotech reported total carbon emissions of approximately 14,340,180 kg CO2e for Scope 1 and about 42,409,680 kg CO2e for Scope 2, with no reported emissions for Scope 3. This represents a slight increase in Scope 1 emissions from 2023, where they were approximately 13,460,580 kg CO2e, and Scope 2 emissions were about 39,507,900 kg CO2e. Concord Biotech has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in initiatives such as the Science Based Targets initiative (SBTi). The company’s emissions data is self-reported and does not cascade from any parent organisation, indicating that all figures are directly attributed to Concord Biotech Limited. The company’s emissions intensity, calculated in terms of physical output, was approximately 23,640,000 kg CO2e for Scope 1 and 2 combined in 2024. This reflects their ongoing efforts to monitor and report emissions, although no formal reduction strategies have been disclosed. Overall, while Concord Biotech is actively tracking its emissions, the absence of reduction targets suggests an opportunity for future climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 13,460,580 | 00,000,000 | 00,000,000 |
| Scope 2 | 39,507,900 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Concord Biotech is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
